SNIPR Biome, a Danish microbiome technology company, has unveiled promising results from the initial phase of their groundbreaking CRISPR-based phage therapy targeting Escherichia coli in the gastrointestinal tract. Imagine a team of microscopic superheroes armed with advanced DNA editing technology. That’s SNIPR001, a powerful blend of four bacteriophages (tiny viruses that specialize in obliterating bacteria) … Continue reading CRISPR-based Phage Therapy Shines in the First Human Trial